SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

CytRx Oncology Corp – ‘8-K’ for 6/7/07

On:  Thursday, 6/7/07, at 3:42pm ET   ·   For:  6/7/07   ·   Accession #:  950123-7-8408   ·   File #:  0-51534

Previous ‘8-K’:  ‘8-K’ on 6/4/07 for 6/2/07   ·   Next:  ‘8-K’ on / for 6/29/07   ·   Latest:  ‘8-K’ on 6/18/08 for 6/16/08

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 6/07/07  CytRx Oncology Corp               8-K:8,9     6/07/07    2:24K                                    RR Donnelley/FA

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     16K 
 2: EX-99.1     Ex-99.1: Press Release                              HTML     14K

8-K   —   Current Report
Document Table of Contents

Page (sequential) | (alphabetic) Top
 
11st Page   -   Filing Submission
"Table of Contents
"Item 8.01. Other Events
"Item 9.01. Financial Statements and Exhibits
"Signatures

This is an HTML Document rendered as filed.  [ Alternative Formats ]

  FORM 8-K  
Table of Contents

 
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 7, 2007
INNOVIVE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
         
Delaware   000-51534   74-3123261
 
(State or other jurisdiction of incorporation)   (Commission File   (IRS Employer ID Number)
    Number)    
555 Madison Avenue, 25th Floor, New York, New York
  10022
 
(Address of principal executive offices)
   (Zip Code)
Registrant’s telephone number, including area code (212) 716-1810
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

TABLE OF CONTENTS

Item 8.01. Other Events
Item 9.01. Financial Statements and Exhibits
SIGNATURES
EX-99.1: PRESS RELEASE

Table of Contents

Item 8.01. Other Events.
On June 7, 2007, Innovive Pharmaceuticals, Inc. issued a press release to announce that the U.S. Food and Drug Administration has granted Fast Track Designation for the company’s drug candidate, Tamibarotene. The press release is attached as an exhibit to this report.
Item 9.01. Financial Statements and Exhibits.
(c)   Exhibits
     
Exhibit    
Number   Description of Document
 
    
99.1
  Press release dated June 7, 2007

 

Table of Contents

SIGNATURES
          Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
 
  INNOVIVE PHARMACEUTICALS, INC.    
 
        
Date: June 7, 2007
  /s/ Steven Kelly
 
Steven Kelly 		   
 
  President and Chief Executive Officer    

 

Dates Referenced Herein

This ‘8-K’ Filing    Date    Other Filings
Filed on / For Period End:6/7/07None on these Dates
 List all Filings 
↑Top
Filing Submission 0000950123-07-008408   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Thu., Apr. 25, 7:16:13.1pm ET